Join
Live feed
·
PRReleasevia Quantisnow
Anavex Life Sciences Corp. logo

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
AVXL· Anavex Life Sciences Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVXL (Anavex Life Sciences Corp.) and more on Quantisnow.